Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CinCor Pharma, Inc.

http://cincor.com

Latest From CinCor Pharma, Inc.

Boehringer To Profit From Jardiance Well Into Second Half Of Decade

The German firm is anticipating a major label expansion in kidney disease for its SGL2 inhibitor later this year, prompting Boehringer to gear up commercial activities as AstraZeneca’s rival Farxiga faces the threat of generic competition.

Sales & Earnings Renal

US IPO Market In 2022 Even Underperformed Normal Years

INFOGRAPHIC: The number of biopharma offerings in 2022 was far below records set in 2020 and 2021, but also below more normal years of 2018 and 2019. The IPO class of 2022 eked out a positive average return, however.

Financing Growth

Deals In Depth: January 2023

Eight $1bn+ alliances were penned in January. Topping the list was a potential $4.4bn deal between Neurocrine Biosciences and Voyager Therapeutics to advance multiple gene therapies for the treatment of neurological diseases.

Deals Financing

AstraZeneca Confident For Next Decade Despite Upcoming Patent Cliff

The UK major believes it can maintain growth trajectory through novel combinations regimens and pipeline diversification despite the anticipated expiration of several blockbuster drug patents over the next decade.

Sales & Earnings Companies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
UsernamePublicRestriction

Register